Context
BioNTech is a leading biotech company pioneering individualized immunotherapies for cancer, with eight clinical-stage candidates and seven partnerships with world-leading pharma and biotech companies.
It operates as a fully integrated global company whose technology platforms include mRNA therapeutics, engineered cellular therapies, antibodies and small molecules, allowing the company to address tumour interindividual variability and bring the right treatment for the right patient.
Clinical results to date have already shown that lead mRNA product BNT111 in melanoma brought clinical benefit to more than 40% of patients. BioNTech expects up to 5 clinical readouts through 2020, including topline results of the Genentech melanoma trial.
IPO proceeds will be used to complete ongoing clinical trials for mRNA cancer vaccines, as well as candidates partnered with Genentech, Sanofi and Genmab, advance products from CAR-T, antibody and TCR platforms to the clinic, and expand manufacturing and laboratory capabilities.
About BioNTech
BioNTech was founded in 2008 on the understanding that every cancer patient’s tumour is unique and therefore, each patient’s treatment should be individualized. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech has established relationships with seven pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and has published over 150 peer-reviewed publications on its scientific approach.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Bookrunner to BioNTech on its USD 150 million Nasdaq Initial Public Offering
Bryan, Garnier & Co acted as Joint Bookrunner on this landmark European biotech transaction.
BioNTech’s USD 150m IPO represents one of the largest direct to NASDAQ IPO for a European biotechnology company and also the second largest NASDAQ raise for a German biotech company to date.
For Bryan, Garnier & Co BioNTech is the seventh European NASDAQ IPO for which Bryan, Garnier & Co has acted in a leadership role, assisting issuers in this critical stage in their growth and financing cycle.
Despite a challenging global market backdrop, Bryan, Garnier & Co assisted BioNTech in finding IPO demand across Europe, as well as the US. More than 90% of European demand came from Tier-1 long-only healthcare specialists.
Share